European Journal of Cancer
Volume 39, Issue 6 , Pages 742-747, April 2003

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours

  • A Awada

      Affiliations

    • Jules Bordet Institute, Bd de Waterloo 125, 1000 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32-2-541-3219; fax: +32-2-538-0858
    • ,
  • R Thödtmann

      Affiliations

    • III. Medizinische Klinik, München, Germany
    • ,
  • M.J Piccart

      Affiliations

    • Jules Bordet Institute, Bd de Waterloo 125, 1000 Brussels, Belgium
    • ,
  • J Wanders

      Affiliations

    • New Drug Development Office, Free University Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • A.H.G.J Schrijvers

      Affiliations

    • New Drug Development Office, Free University Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    • ,
  • I.-M Von Broen

      Affiliations

    • Knoll AG, Knollstrasse, 67061 Ludwigshafen, Germany
    • ,
  • A.R Hanauske

      Affiliations

    • AK St. Georg, Division of Medical Oncology, I. Dept of Medicine, Lohmühlenstrasse 5, 20099 Hamburg, Germany

Received 17 October 2002; accepted 28 October 2002.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0959-8049(02)00776-1

doi:10.1016/S0959-8049(02)00776-1

European Journal of Cancer
Volume 39, Issue 6 , Pages 742-747, April 2003

Article Tools

* Image Usage & Resolution